首页> 外文期刊>Medicine. >Efficacy of human coronavirus immune convalescent plasma for the treatment of corona virus disease -19 disease in hospitalized children: A protocol for systematic review and meta analysis
【24h】

Efficacy of human coronavirus immune convalescent plasma for the treatment of corona virus disease -19 disease in hospitalized children: A protocol for systematic review and meta analysis

机译:人冠状病毒免疫促进等离子体治疗住院儿童电晕病毒病-19疾病的疗效:系统审查和元分析的议定书

获取原文
           

摘要

Background: Severe acute respiratory syndrome coronavirus 2 viral infection resulting in corona virus disease 2019 (COVID-19) disease has recently been designated by the World Health Organization as a global pandemic. Some doctors are using convalescent plasma (CP) therapies to treat COVID-19 patients. However, whether CP therapy is effective for children with COVID-19 remains controversial. Therefore, this study further explores the effectiveness and safety of human coronavirus immune CP in the treatment of COVID-19 in children. Methods: Comprehensively search the electronic databases such as the Cochrane Library, PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, and WanFang, and collect relevant documents. We will also look for other sources. All document sources will not be restricted by language and publication status. Two researchers will independently conduct research selection, data extraction and research quality assessment. RevMan 5.3 was used for statistical analysis. Results: This study will provide high-quality comprehensive evidence for the effectiveness and safety of human coronavirus immuno CP in the treatment of COVID-19 in children Conclusions: The results of this study will provide the basis for the effectiveness and safety of human coronavirus immuno CP treatment of COVID-19 in children.
机译:背景:严重急性呼吸综合征冠状病毒2病毒感染导致电晕病毒疾病2019(Covid-19)疾病最近被世界卫生组织作为全球大流行指定。一些医生正在使用康复等离子体(CP)治疗Covid-19患者。但是,CP疗法是否对Covid-19的儿童有效仍然存在争议。因此,本研究进一步探讨了人冠状病毒免疫CP在儿童Covid-19治疗中的有效性和安全性。方法:全面搜索电子数据库,如Cochrane图书馆,PubMed,Embase,Science,中国国家知识基础设施和Wanfang,并收集相关文件。我们也将寻找其他来源。所有文档来源都不会受到语言和出版状态的限制。两位研究人员将独立开展研究选择,数据提取和研究质量评估。 Revman 5.3用于统计分析。结果:本研究将为人类冠状病毒免疫CP治疗儿童Covid-19的疗效和安全提供高质量的综合证据:本研究的结果将为人冠状病毒免疫力的有效性和安全性提供基础CP治疗Covid-19儿童。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号